High rate of lymphoma patients respond to Bristol-Myers drug-study

Dec 6 (Reuters) - Eighty-seven percent of Hodgkin lymphoma patients responded to a Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday.